Cell Therapeutics (CTI) Cancer Therapies and Cancer Drug Development Home Page

Latest News

May. 10, 2012: Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
Apr. 20, 2012: Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Apr. 19, 2012: Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
Apr. 19, 2012: Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis

View all news releases

April 20, 2012Q1 2012 Cell Therapeutics, Inc. Earnings Conference Call 8:30 a.m. EDTWebcast

April 19, 2012Cell Therapeutics, Inc. (CTI) Conference Call on Pacritinib Acquisition 8:30 a.m. EDTWebcast

March 7, 2012Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter 2011 Financial Results
8:30 a.m. EDTWebcast

Helpful Resources for Patients

Find Ongoing Clinical Trials

Close Window [X]

Cell Therapeutics, Inc. is continuing the clinical development of pixantrone with the Phase III PIX-R TRIAL.

If you would like more information about this trial, please submit the following form to stay updated, or visit www.pixrtrial.com